Zealand Pharma A/S Stock OTC Markets
Stocks
ZLDPY
US98920Y1064
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
13:57:04 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 8.670 USD | -2.03% |
|
-2.03% | -45.81% |
| 09-16 | Zealand Pharma A/S Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 11:30 AM | |
| 09-15 | Elvinix licenses diabetes portfolio from Zealand Pharma | FW |
| Market Cap | 19.27B 2.96B 2.58B 2.44B 2.22B 4.14B 283B 4.16B 29.06B 11.23B 144B 11.12B 10.87B 461B | P/E 2026 * |
9.79x | P/E 2027 * | 28.1x |
|---|---|---|---|---|---|
| Enterprise Value | 8.66B 1.33B 1.16B 1.1B 996M 1.86B 127B 1.87B 13.05B 5.05B 64.7B 4.99B 4.88B 207B | EV / Sales 2026 * |
1.78x | EV / Sales 2027 * | 1.94x |
| Free-Float |
95.75% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
OTC Markets
| ZLDPY | Delayed | |
Deutsche Boerse AG
| 22Z1 | Delayed |
Last Transcript: Zealand Pharma A/S
| 1 day | -2.03% | ||
| 1 week | -2.03% | ||
| Current month | -2.03% | ||
| 1 month | -6.87% | ||
| 3 months | -12.42% | ||
| 6 months | -14.92% | ||
| Current year | -45.81% |
| 1 month | 8.67 |  | 8.85 |
| Current year | 7.75 | | 14.27 |
| 1 year | 7.75 | | 16 |
| 3 years | 7.75 | | 70.16 |
| 5 years | 7.75 | | 70.16 |
| 10 years | 7.75 | | 70.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 2022-03-29 | |
| Director of Finance/CFO | - | 2022-10-31 | |
Utpal Singh
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-22 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
Kirsten Drejer
BRD | Director/Board Member | 69 | 2018-04-18 |
Leonard Kruimer
BRD | Director/Board Member | 68 | 2019-04-03 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.03% | -2.03% | - | - | 2.87B | |
| +1.76% | +3.88% | +46.85% | +101.12% | 69.69B | |
| +2.29% | +1.43% | +38.39% | +77.03% | 61.24B | |
| +1.14% | -2.59% | -14.37% | +365.92% | 26.77B | |
| +2.95% | +2.34% | +0.52% | -12.74% | 24.07B | |
| +1.49% | +7.73% | +26.85% | -15.89% | 20.39B | |
| -0.83% | -9.47% | +174.16% | +295.44% | 15.72B | |
| +3.01% | +1.85% | +44.63% | +168.18% | 14.07B | |
| +2.43% | +4.24% | -2.05% | +847.59% | 13.8B | |
| +1.00% | +0.24% | +28.02% | +203.83% | 12.22B | |
| Average | +1.32% | +0.66% | +38.11% | +225.61% | 28.66B | |
| Weighted average by Cap. | +1.78% | +1.73% | +36.71% | +163.30% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.86B 747M 650M 616M 559M 1.04B 71.52B 1.05B 7.33B 2.84B 36.35B 2.81B 2.74B 116B | 4.2B 645M 561M 531M 483M 902M 61.73B 906M 6.33B 2.45B 31.37B 2.42B 2.37B 100B |
| Net income | 2.03B 312M 272M 257M 234M 437M 29.88B 439M 3.06B 1.18B 15.19B 1.17B 1.15B 48.62B | 580M 89.03M 77.54M 73.39M 66.68M 125M 8.53B 125M 874M 338M 4.33B 334M 327M 13.87B |
| Net Debt | -10.61B -1.63B -1.42B -1.34B -1.22B -2.28B -156B -2.29B -16B -6.19B -79.33B -6.12B -5.99B -254B | -11.13B -1.71B -1.49B -1.41B -1.28B -2.39B -164B -2.4B -16.78B -6.49B -83.17B -6.42B -6.28B -266B |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZEAL Stock
- ZLDPY Stock
Select your edition
All financial news and data tailored to specific country editions
